



BIOMÉRIEUX



BIOMÉRIEUX

# bioMérieux

## *In vitro* diagnostics serving public health

---

A major player in *in vitro* diagnostics for more than 50 years, bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide.

Our diagnostic solutions bring high medical value to healthcare professionals, providing them with the most relevant and reliable information, as quickly as possible, to support treatment decisions and better patient care.

bioMérieux's mission entails a commitment to support medical education, by promoting access to diagnostic knowledge for as many people as possible. Focusing on the medical value of diagnostics, our collection of educational booklets aims to raise awareness of the essential role that diagnostic test results play in healthcare decisions.

Other educational booklets are available.  
Consult your local bioMérieux representative.

The information in this booklet is for educational purposes only and is not intended to be exhaustive. It is not intended to be a substitute for professional medical advice. Always consult a medical director, physician, or other qualified health provider regarding processes and/or protocols for diagnosis and treatment of a medical condition. bioMérieux assumes no responsibility or liability for any diagnosis established or treatment prescribed by the physician.

---

bioMérieux S.A. • 69280 Marcy l'Étoile • France  
Tel.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90  
[www.biomerieux.com](http://www.biomerieux.com) • [www.biomerieux.com/d-dimer](http://www.biomerieux.com/d-dimer)

# D-DIMER

for exclusion of venous thromboembolism



PIONEERING DIAGNOSTICS



This booklet provides clinicians and laboratory managers with concise information on the pathophysiology and diagnosis of VTE, with special emphasis on the role of D-dimer, including criteria for its use as a valid exclusion test.

## OUR SPECIAL THANKS GO TO

**Prof Marc Righini, MD**

(Division of Angiology and Hemostasis, Department of Medical Specialties, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland)

*for his expert advice in preparing this booklet.*

## INTRODUCTION

**Accurate, early diagnosis of VTE (DVT/PE)** is critical to prevent complications and risk of death. Imaging techniques are required for a positive diagnosis, including compression ultrasound (CUS) and CT pulmonary angiography (CTPA) for diagnosis of DVT and PE, respectively<sup>(1)</sup>.

However, the low prevalence of confirmed VTE in suspected outpatients (20% or less) underscores the importance of a **first triage by a non-invasive exclusion test** in order to **avoid unnecessary imaging**<sup>(2)</sup>. Imaging is not only costly, but in the case of CTPA can also cause harm: cancer risk due to radiation exposure, contrast-induced nephropathy and excess bleeding risk associated with unnecessary use of anticoagulants in case of over-diagnosis<sup>(3)</sup>.

Over the past 25 years, the clinical usefulness of **D-dimer** testing in the diagnosis of patients with suspected VTE has been extensively validated<sup>(4)</sup>:

- Due to its **high sensitivity** for the presence of VTE, D-dimer allows its exclusion in suspected patients attending the emergency department (ED).
- For safety reasons, VTE exclusion by the D-dimer test should be restricted to patients with a **non-high or an unlikely clinical probability** for having VTE as assessed by validated **clinical prediction rules**.
- Due to its **low specificity** for the presence of VTE, D-dimer cannot be used as a **rule-in test**.

Consequently, the diagnostic management of DVT and PE is based on **sequential use of tests**, including clinical probability assessment, D-dimer and imaging techniques<sup>(1)</sup>. These **diagnostic algorithms** have been extensively validated in outcome studies<sup>(5)</sup>.

- Combined use of **clinical prediction rules** and **D-dimer testing as first screen** allows rapid identification of patients who do not require imaging and in whom anticoagulant treatment can be safely withheld.
- This is a **cost-effective** approach that **avoids unnecessary imaging** in about **1/3<sup>rd</sup> of outpatients with suspected VTE**.

D-dimer assays are **widely available, but vary considerably in their analytical, operational and clinical performance characteristics**<sup>(4)</sup>. Clinicians and laboratory managers should be aware of these aspects before selecting a D-dimer assay for VTE exclusion. Furthermore, clinicians should also understand the limitations of the D-dimer test for VTE exclusion within the clinical context of the patient<sup>(4,6)</sup>.



# VENOUS THROMBOEMBOLISM (VTE)

A 'SILENT KILLER' AND MAJOR CAUSE OF GLOBAL DISEASE BURDEN <sup>(7)</sup>

## HIGH INCIDENCE <sup>(7)</sup>

- In the general Caucasian population, between 1 and 2 per 1000 develop VTE each year (about 2/3<sup>rd</sup> DVT and about 1/3<sup>rd</sup> PE), with a slightly higher incidence in men than women.
- Annual incidence rises with age to between 2 and 7 per 1000 after 70 years of age.
- Although the annual incidence is lower in Asians (< 0.5 per 1000) their disease burden is not low due to population aging.
- Up to 60% of VTE events occur during or after hospitalization, making it a leading preventable cause of hospital death.

## HIGH MORTALITY

- VTE is a medical emergency because PE can be life-threatening if not treated immediately. It has been estimated that of all VTE-related deaths, 34% are due to sudden fatal PE, 59% result from PE that remained undiagnosed and 7% of early deaths were correctly diagnosed with PE <sup>(8)</sup>.
- In the USA and EU, more than 800,000 VTE-related deaths are estimated to occur each year, making VTE the third most frequent cause of cardiovascular mortality after heart attack and stroke <sup>(7)</sup>.

## CHRONIC RELAPSING DISEASE WITH HIGH MORBIDITY

- VTE has a high risk of recurrence: 11% within the first year, and 40% within 10 years <sup>(9)</sup>.
- Long-term, VTE is associated with considerable disability <sup>(7)</sup>.
- Approximately 10-20% of DVT patients develop severe post-thrombotic syndrome (PTS). This is a chronic disorder with decreased quality of life and reduced capacity to walk and to work, particularly due to development of venous ulcers.
- Up to 4% of PE patients develop chronic thromboembolic pulmonary hypertension (CTEPH), characterized by reduced cardiorespiratory capacity.

## HIGH ECONOMIC BURDEN

- VTE costs, the majority related to PE, have a large impact on the healthcare system <sup>(10)</sup>. Including long-term morbidity (PTS, CTEPH), total annual VTE costs between 15 and 34 billion USD have been estimated for the US healthcare system.
- Total VTE-related healthcare costs of 640 million GBP have been reported in the UK <sup>(8)</sup>.

# VENOUS THROMBOEMBOLISM

## Definition and classification

➤ **Venous thromboembolism (VTE)** results from the presence of a clot in the venous circulation (lower or upper extremity veins in particular) and/or by embolization of parts of the clot into the pulmonary circulation<sup>(11)</sup>.

➤ Consequently, **deep vein thrombosis (DVT)** and **pulmonary embolism (PE)** are two clinical manifestations of the same disease. Asymptomatic PE is present in patients with proximal DVT, whereas asymptomatic DVT can also be detected in patients with PE<sup>(12)</sup>.

Clot formation in the leg veins may occur at various sites (**Figure 1**). Venous thrombosis of the upper extremity, defined as a thrombus in the subclavian, axillary or brachial vein, accounts for 4-10% of all venous thromboses and is often asymptomatic<sup>(13)</sup>.


## VENOUS THROMBOEMBOLISM

**Figure 1: Types of acute DVT<sup>(11)</sup>**

1. **Ascending DVT** is the most common type of DVT. The clot originates in the calf muscle veins (distal DVT) and extends to reach the proximal femoral or iliac veins. Propagation into proximal veins may occur within days or even hours but can also take weeks.

2. **Transfacial thrombosis** originates in the superficial veins of the leg (greater or lesser saphenous vein). It can propagate proximally and may turn from superficial into deep vein thrombosis.

3. **Descending iliofemoral DVT** originates in the iliac veins, primarily the left iliac vein. Thrombotic obstruction of the iliac vein can develop within hours leading to massive leg swelling, pain and discoloration.



**The risk for PE becomes significant** in the presence of a thrombus that extends into the popliteal veins or above (**proximal DVT**). Parts of the clot may break off from an actively propagating thrombus in the leg veins and embolize into the pulmonary circulation (transport through the superior vena cava, pass the right heart into the pulmonary arteries).


The nature and severity of symptoms depends on the size and location of the embolized thrombus (**Figure 2**).

**Figure 2: Types of acute PE<sup>(11)</sup>**

1. **Peripheral, sub-segmental PE** is a mild form of PE characterized by pulmonary hemorrhagic infarction (local alterations of lung tissue with pleuritic pain or hemoptysis).

2. **Central, segmental or lobar PE** is a moderate form of PE characterized by isolated dyspnea (high probability V/Q lung scan in majority of cases).

3. **Central PE with massive pulmonary artery obstruction** is a severe form of PE associated with circulatory collapse (cardiac dysfunction).



## Pathophysiology and risk factors

**Pathophysiological mechanisms** underlying venous thrombosis can be classified into **three categories**, known as **Virchow's triad**, according to **disturbances** of <sup>(1)</sup>:

- Blood flow (venous stasis, e.g. due to immobilization, obesity, heart failure).
- Blood vessel wall (e.g. due to surgery or trauma).
- Blood constituents (e.g. due to inheritable thrombophilia, drugs, pregnancy).

VTE is a **multifactorial disease** and in most cases more than one risk factor can be identified <sup>(14)</sup>. The risk for VTE increases in proportion to the number of predisposing factors as well as the magnitude of the risk of each individual factor.

Currently recognized **clinical VTE risk factors** and the magnitude of their risk are listed in **Table 1** <sup>(15)</sup>. The most frequent risk factors include **older age, obesity, history of VTE, cancer, long bed rest and major surgery** <sup>(15)</sup>. Considering temporal relationships, risk factors can be **transient** (e.g. trauma, surgery) or **chronic** (e.g. metastatic cancer, thrombophilia). Furthermore, risk factors can be **genetic** (heritable thrombophilia) or **acquired**.

In 26-47% of cases, patients with a **first episode of VTE** do not have any identifiable precipitating cause or risk factor. These patients are referred to as having **idiopathic or unprovoked VTE** <sup>(16)</sup>.

**Knowledge of risk factors is important in the clinical management of VTE:**

- **PREVENTION**  
To identify high-risk groups in whom **prophylactic treatment** is indicated <sup>(17)</sup>.
- **DIAGNOSIS**  
To aid in **clinical pre-test probability assessment** (see clinical prediction rules), the first step to guide the optimal diagnostic strategy <sup>(1)</sup>.
- **TREATMENT**  
To guide the **optimal duration of anticoagulant therapy** after a VTE event <sup>(18)</sup>.

**Table 1: Risk factors for VTE** <sup>(15)</sup>

### STRONG RISK FACTORS (ODDS RATIO > 10)

- Fracture of lower limb
- Hospitalization for heart failure or atrial fibrillation/flutter (within previous 3 months)
- Hip or knee replacement
- Major trauma
- Myocardial infarction (within previous 3 months)
- Previous venous thromboembolism
- Spinal cord injury

### MODERATE RISK FACTORS (ODDS RATIO 2-9)

- Arthroscopic knee surgery
- Auto-immune diseases
- Blood transfusion
- Central venous lines
- Chemotherapy
- Congestive heart or respiratory failure
- Erythropoiesis-stimulating agents
- Hormone replacement therapy (depends on formulation)
- In vitro* fertilization
- Infection (specifically pneumonia, urinary tract infection and HIV)
- Inflammatory bowel disease
- Cancer (highest risk in metastatic disease)
- Oral contraceptive therapy
- Paralytic stroke
- Postpartum period
- Superficial vein thrombosis
- Thrombophilia

### WEAK RISK FACTORS (ODDS RATIO < 2)

- Bed rest >3 days
- Diabetes mellitus
- Hypertension
- Immobility due to sitting (e.g. prolonged car or air travel)
- Increasing age
- Laparoscopic surgery (e.g. cholecystectomy)
- Obesity
- Pregnancy
- Varicose veins

## Signs and symptoms

Typical **symptoms of DVT** include swelling and/or **pain in the affected leg** as well as tenderness, increased **warmth, erythema** or distended superficial veins. DVT can also be asymptomatic. Because PE is a consequence of DVT, signs of DVT may also be present in patients with PE.

The **suspicion of PE** is particularly raised in patients presenting with **dyspnea/tachypnea, pleuritic chest pain**, syncope, hemoptysis or with sudden hemodynamic instability (shock or hypotension). In most clinical studies, suspected PE has been defined as “**acute onset of new or worsening shortness of breath or chest pain without any other obvious cause**”<sup>(19)</sup>.

These signs and symptoms are neither sensitive nor specific for DVT or PE and many **alternative diagnoses** need to be considered (Table 2). The medical history and the presence of risk factors (see Table 1) are other important clues in judging the clinical probability of VTE.

➔ The integration of multiple clinical factors into a **clinical prediction rule (CPR)** is a quick and easy way to discriminate suspected VTE patients into three categories of **pretest probability (PTP)**: low, intermediate and high; or in two categories of pre-test clinical probability: unlikely and likely.

➔ The clinical pretest probability **guides the diagnostic work-up**.

Table 2: Differential diagnosis

SUSPECTED DVT	SUSPECTED PE
Muscle strain or tear	Pneumonia
Arthritis of the knee or ankle including gout	Acute bronchitis
Ruptured Baker’s cyst	Pneumothorax
Hematoma	Acute pulmonary edema
Calf muscle abscess	Pulmonary neoplasm
Lymphangitis	Myocardial infarction
Lymphedema	Muscle strain
Cellulitis	Rib fracture
Varicose veins	
Venous reflux	
Vasomotor changes (e.g. in paralyzed leg)	
Superficial venous thrombosis	
Post-thrombotic syndrome	

The most commonly used and best validated CPR’s are the **Wells scores for DVT (Table 3) and PE (Table 4)** and the **revised Geneva score for PE (Table 5)**. All these scores also allow dichotomization into two categories: DVT/PE unlikely and DVT/PE likely. Simplified versions of the CPR’s for PE, with 1 point for each variable in the rule, have also been validated<sup>(15)</sup>. The typical distribution of PTP categories and disease prevalence in each category is summarized in Table 6.

Table 3: Clinical prediction rule for DVT: the Wells score<sup>(20, 21)</sup>

CLINICAL FEATURE	POINTS
<b>RISK FACTORS</b>	
• Active cancer (treatment ongoing, within previous 6 month or palliative)	<b>1</b>
• Paralysis, paresis, or recent plaster immobilization of the lower extremities	<b>1</b>
• Recently bedridden >3 days or major surgery within previous 12 weeks requiring general or regional anesthesia	<b>1</b>
• Previously documented DVT	<b>1</b>
<b>CLINICAL SIGNS, SYMPTOMS*</b>	
• Localized tenderness along the distribution of the deep venous system	<b>1</b>
• Entire leg swollen	<b>1</b>
• Calf swelling 3 cm larger than asymptomatic side (measured 10 cm below tibial tuberosity)	<b>1</b>
• Pitting edema confined to the symptomatic leg	<b>1</b>
• Collateral superficial veins (non-varicose)	<b>1</b>
<b>CLINICAL JUDGMENT</b>	
• Alternative diagnosis at least as likely as DVT	<b>-2</b>
<b>CLINICAL PROBABILITY (3 LEVELS)</b>	<b>TOTAL</b>
● Low	≤0
● Intermediate	1 or 2
● High	≥3
<b>CLINICAL PROBABILITY (2 LEVELS)</b>	<b>TOTAL</b>
■ DVT unlikely	<2
■ DVT likely	≥2

\* In patients with symptoms in both legs, the more symptomatic leg is used.

Table 4: Clinical prediction rule for PE: the Wells score.

CLINICAL FEATURE	POINTS	
	ORIGINAL <sup>(22)</sup>	SIMPLIFIED <sup>(23)</sup>
<b>RISK FACTORS</b>		
• Previous DVT or PE	1.5	1
• Surgery or bedridden for 3 days during past 4 weeks	1.5	1
• Active cancer (treatment within 6 months or palliative)	1	1
<b>CLINICAL SIGNS, SYMPTOMS</b>		
• Hemoptysis	1	1
• Heart rate > 100 beats/min	1.5	1
• Clinical signs of DVT	3	1
<b>CLINICAL JUDGMENT</b>		
• Alternative diagnosis less likely than PE	3	1
<b>CLINICAL PROBABILITY (3 LEVELS)</b>	TOTAL	TOTAL
● Low	0-1	NA
● Intermediate	2-6	NA
● High	≥ 7	NA
<b>CLINICAL PROBABILITY (2 LEVELS)</b>	TOTAL	TOTAL
■ PE unlikely	0-4	0-1
■ PE likely	≥ 5	≥ 2

Table 5: Clinical prediction rule for PE: the revised Geneva score.

CLINICAL FEATURE	POINTS	
	ORIGINAL <sup>(19)</sup>	SIMPLIFIED <sup>(24)</sup>
<b>RISK FACTORS</b>		
• Age > 65 years	1	1
• Previous DVT or PE	3	1
• Surgery or fracture within 1 month	2	1
• Active malignancy	2	1
<b>CLINICAL SIGNS, SYMPTOMS</b>		
• Unilateral lower limb pain	3	1
• Hemoptysis	2	1
• Heart rate		
75-94 beats/min	3	1
≥95 beats/min	5	2
• Pain on deep palpation of lower limb and unilateral edema	4	
<b>CLINICAL PROBABILITY (3 LEVELS)</b>	TOTAL	TOTAL
● Low	0-3	0-1
● Intermediate	4-10	2-4
● High	≥ 11	≥ 5
<b>CLINICAL PROBABILITY (2 LEVELS)</b>	TOTAL	TOTAL
■ PE unlikely	0-5	0-2
■ PE likely	≥ 6	≥ 3

Table 6: Pretest probability distribution and VTE prevalence.

PTP category	Wells score DVT		Wells score PE		Revised Geneva score PE	
	% of Total	DVT (%)	% of Total	PE (%)	% of Total	PE (%)
<b>3 LEVEL SCORE</b>	(data from ref 25)		(data from ref 26)		(data from ref 26)	
Low	44	5	59	6	36	9
Intermediate	36	17	35	23	59	26
High	20	53	6	49	5	76
<b>TOTAL</b>	<b>100</b>	<b>19</b>	<b>100</b>	<b>12</b>	<b>100</b>	<b>22</b>
<b>2 LEVEL SCORE</b>	(data from ref 21)		(data from ref 26)		(data from ref 24)	
Unlikely	54	6	69	8	65	12
Likely	45	28	31	34	35	42
<b>TOTAL</b>	<b>100</b>	<b>16</b>	<b>100</b>	<b>16</b>	<b>100</b>	<b>22</b>

## Diagnosis NON-INVASIVE ALGORITHM

An accurate and rapid diagnosis of VTE in suspected patients is essential. Missing the diagnosis may result in a potentially fatal PE, whereas a false positive diagnosis may lead to unnecessary anticoagulant treatment that is associated with bleeding risk that can be fatal.

**MISSING THE DIAGNOSIS**  
➡ Potentially fatal PE

**FALSE-POSITIVE RESULT**  
➡ Unnecessary anticoagulants (risk of fatal bleeding)

Furthermore, as a result of the raised index of clinical suspicion, the prevalence of confirmed VTE among suspected outpatients has dramatically declined over recent years to values as low as 10% or less in certain populations<sup>(2)</sup>. This explains the need for an efficient non-invasive approach to safely exclude VTE and to identify those patients in whom anticoagulant therapy can be withheld.

In the vast majority of patients, a **non-invasive work-up** is feasible. This consists of the sequential use of a **CPR** for **clinical pretest probability** assessment, **D-dimer** and **imaging** techniques (Figure 3)<sup>(1)</sup>. Preferred imaging methodologies are **compression ultrasound (CUS)** for diagnosis of DVT and **computerized tomographic pulmonary angiography (CTPA)** for diagnosis of PE (Figure 4).

Although CTPA is the most reliable test for the diagnosis of PE, algorithms using **V/Q scanning** are equally safe and may be preferred in populations where radiation exposure is a concern (e.g. breast cancer risk in young women)<sup>(27)</sup>.

➤ **Clinical assessment and D-dimer are recommended as the first step in the investigation of patients with suspected VTE**<sup>(1,4,15)</sup>. This strategy is cost-efficient<sup>(28)</sup> and safely excludes VTE in 30-50% of suspected outpatients<sup>(5)</sup>.


➤ In case of a **high pretest probability** or a **positive D-dimer**, objective **confirmation** is needed by **CUS** in case of suspected DVT or **CTPA** in case of suspected PE<sup>(1)</sup>.

Given its **high negative predictive value (NPV)**, D-dimer plays a **key role in rapid exclusion of VTE**. It is important to realize that the NPV will drop with increasing prevalence of VTE (pretest probability) and this rate of decline is determined by the sensitivity of the D-dimer assay (see Figure 6, page 18).

➤ **Highly sensitive D-dimer** assays permit **safe exclusion** in patients with **low and intermediate PTP**, whereas a **less sensitive D-dimer** assay should be limited to patients with **low or unlikely PTP**<sup>(4)</sup>.

➤ **D-dimer** should **NOT** be used in patients with **high PTP**, because despite a normal D-dimer level, approximately 1 in 10 patients may still have PE<sup>(29)</sup>.

Figure 3: Diagnostic algorithm for suspected DVT or PE in outpatients<sup>(1,4,15)</sup>




➤ In this algorithm, the **D-dimer** result refers to a **highly sensitive assay**. With less sensitive assays, exclusion is only possible in patients with a low (or unlikely) pretest probability.

➤ In case of **suspected PE**, this algorithm is only valid when the patient is **hemodynamically stable**<sup>(15)</sup>. With shock or hypotension, immediate CTPA or echocardiography (when CTPA is not available) is needed.



Adherence to above validated diagnostic strategy is crucial for diagnosing PE because of the 4-fold higher risk of recurrent PE and death when the diagnosis is missed<sup>(30)</sup>. Furthermore, significantly fewer patients will receive an unnecessary radiation dose when the algorithm is correctly followed<sup>(31)</sup>.

Figure 4: VTE diagnosis by imaging<sup>(1)</sup>



DVT is detected by compression ultrasonography (CUS, left) and PE by CT pulmonary angiography (CTPA, right). CUS directly visualizes the proximal veins in the leg which are subsequently assessed for their compressibility. Non-compressibility is diagnostic for acute proximal DVT with a sensitivity of 94% and specificity of 98%. A CTPA is performed after injection of intravenous contrast material. Multi-detector row CT scanners have a high sensitivity (96–100%) and specificity (97–98%) for acute PE.

## PE prognosis

### IMPACT ON PATIENT MANAGEMENT

Decisions on **clinical management** of PE in the acute phase are **guided** by the assessment of the patient's **early death risk** (in-hospital or 30 days)<sup>(15, 32)</sup>. Short-term mortality risk varies widely from 15% or more within hours after admission in hemodynamically unstable patients with shock or hypotension to less than 1% in normotensive patients without signs of right ventricular dysfunction (RVD).

**Risk assessment of acute PE integrates clinical parameters, signs of RVD and measurement of cardiac biomarkers (Table 7).**

**Risk-adjusted management strategies are recommended in guidelines<sup>(15)</sup>:**

- **High risk (massive PE):** This refers to the less than 5% of acute PE patients who present with shock or hypotension. These patients are candidates for **aggressive intervention with thrombolysis or embolectomy** (primary reperfusion).
- **Intermediate risk (submassive PE):** These patients require **hospital admission** and standard **anticoagulation** therapy. Monitoring for signs of hemodynamic decompensation may be required.
- **Low risk:** The majority of patients (up to 50%) are in this category and can be considered for **early discharge and home treatment**<sup>(33)</sup>.

Table 7: Acute PE: risk stratification and management (ESC Guidelines)<sup>(15)</sup>

EARLY MORTALITY RISK	RISK PARAMETERS				CLINICAL MANAGEMENT
	Shock or hypotension	PESI Class III-V or sPESI ≥1	Signs of RVD	Positive cardiac biomarkers	
HIGH	Yes	Yes (**)	Yes	Yes (*)	Primary reperfusion
INTERMEDIATE-HIGH	No	Yes	Yes	Yes	Anticoagulation and hospital admission, monitoring, consider rescue reperfusion
INTERMEDIATE-LOW	No	Yes No (**)	Yes No No	No Yes No	Anticoagulation and hospital admission
LOW	No	No (**)	No (***)	No (***)	Anticoagulation, consider early discharge and home treatment

**PESI:** Pulmonary Embolism Severity Index; **sPESI:** simplified Pulmonary Embolism Severity Index. PESI Class III to V indicates moderate (3-10%) to very high 30-day mortality risk (10-25%); sPESI ≥1 indicate high 30-day mortality risk (11%). Patients in PESI Class I or II or 0 points on sPESI are at low risk for 30-day mortality (<2%).

**RVD:** right ventricular dysfunction assessed on imaging (echocardiography or CTPA).

**Cardiac biomarkers:** markers of myocardial injury (cardiac troponin I or T) or markers of heart failure (B-type natriuretic peptides BNP or NT-proBNP).

\* Assessment not necessary in patients with shock or hypotension

\*\* PESI Class I or II; sPESI =0.


\*\*\* Assessment optional

# D-DIMER

## Definition - Biochemistry

D-dimer is a marker of activation of coagulation and fibrinolysis (Figure 5). Coagulation results in the formation of the fibrin clot, whereas subsequent degradation by the fibrinolytic system generates a heterogeneous mixture of fibrin degradation products characterized by the presence of multiple D-dimer epitopes.

**Figure 5: D-dimer is a marker of fibrin clot formation and dissolution** <sup>(34)</sup>.



Fibrinogen consists of two D-domains separated by a central E domain. The insoluble fibrin clot is formed by the polymerization of fibrin monomers that are generated by thrombin. Fibrin is stabilized by the formation of covalent crosslinks between two adjacent D-domains (this creates the D-dimer epitope). Lysis of fibrin by plasmin results in the generation of a mixture of soluble fibrin degradation products of variable size containing multiple D-dimer epitopes.

Small amounts of D-dimer are present in plasma from healthy individuals because of the continuous physiological turnover (fibrin formation and lysis) of 2-3% of plasma fibrinogen.

❑ In VTE patients, the lysis of obstructing blood clots results in about **8-fold increased plasma D-dimer levels**, which fall with the duration of symptoms and anticoagulant treatment (plasma half-life is approximately 8 hours)<sup>(4)</sup>.

❑ Since **D-dimer** levels are raised in almost all patients with acute VTE when assayed with a **highly sensitive test**, a patient with a **normal plasma level** (i.e. below a predefined cut-off level) is **very unlikely to have DVT or PE**. Therefore, the usefulness of D-dimer lies in its ability to **exclude the presence of VTE**.

D-dimer is not specific for VTE and elevated levels are also observed in a variety of other conditions where activation of coagulation and fibrinolysis occurs (Table 8). This makes D-dimer less useful for VTE exclusion in hospitalized patients due to the high proportion of comorbid conditions with elevated D-dimer.

**Table 8: Elevated D-dimer in absence of VTE** <sup>(4, 34, 35)</sup>

Infection
Inflammation (e.g. inflammatory bowel disease)
Cancer
Surgery
Trauma, extensive burns
Disseminated intravascular coagulation (DIC)
Acute respiratory distress syndrome
Liver or renal disease
Pregnancy
Older age
Acute coronary syndrome
Heart failure
Atrial fibrillation
Stroke
Acute aortic dissection
Peripheral arterial disease

## D-dimer assays

### ACCURACY AND CRITERIA FOR A VALID EXCLUSION TEST

D-dimer levels can be measured by a variety of commercially available tests based on **monoclonal antibodies reactive against D-dimer epitopes** present on fibrin degradation products without cross-reactivity with fibrinogen<sup>(4, 35)</sup>. Detection technology is based on **sandwich-type ELISA**, latex particle agglutination or direct whole blood agglutination.

**D-dimer assays differ in their analytical, operational and clinical performance characteristics.** They can be quantitative or qualitative, manual or fully automated, based on plasma or whole blood samples. The accuracy for VTE varies between assays with an inverse relationship between sensitivity and specificity. Quantitative automated assays have a high sensitivity (>95%) with a low specificity (40-50%), whereas manual whole blood agglutination assays have a lower sensitivity (~85%) but a higher specificity (~70%)<sup>(36)</sup>. Quantitative enzyme-linked fluorescence assays (ELFA) offer the highest sensitivity (99%).

**Because of the trade-off between sensitivity and specificity, clinicians should understand the diagnostic performance of the test used in their institution.**

- The **sensitivity** determines the **safety** of the D-dimer assay for VTE exclusion and should be close to 100% to minimize the number of false negatives (NPV ≥ 98%) over a large pre-test probability range (**Figure 6**). **Guidelines** of the **Clinical Laboratory Standards Institute (CLSI)** recommend a **minimum sensitivity of 97%** in order for the **NPV** to reach a level of **98% or more** in patients with low or intermediate PTP<sup>(37)</sup>.
- The **specificity** determines the **clinical usefulness** (efficacy) of the assay in terms of the proportion of suspected VTE patients that can be excluded. The higher the specificity, the lower the number of positives that require further imaging to confirm the diagnosis.
- An **optimal balance between sensitivity and specificity** is required in order to safely exclude VTE (NPV ≥ 98%) and to avoid further imaging in a large enough proportion of suspected outpatients. This **favors a high-sensitivity D-dimer assay** because it can be used in both the low and intermediate PTP groups (**Figure 6**).

D-dimer assays **lack standardization** and the results depend on the assay being used<sup>(4)</sup>. D-dimer assays usually correlate, but results are not identical because of differences in antibody reactivity, analytical sensitivity, calibrator material and reporting units. This means that each D-dimer assay has its own method-specific cut-off value for VTE exclusion that needs to be clinically validated.


The ultimate **clinical validation** is a **prospective outcome study** with a **3-month follow-up** in excluded patients to detect delayed thrombotic events and establish the true diagnostic performance of the test. The exclusion procedure (i.e. combination of PTP and negative D-dimer) is considered safe if the upper 95% confidence limit of the 3-month thromboembolic failure rate does not exceed 3%<sup>(38)</sup>.

- Selection of the most **appropriate D-dimer assay for VTE exclusion** involves an assessment of **analytical, operational and clinical performance** characteristics (**Table 9**).
- Preference should be given to assays that have undergone **proper clinical validation** and have a sufficiently **low coefficient of variation at the cut-off point**<sup>(4)</sup>.

**Table 9: Requirements of a D-dimer assay for VTE exclusion**<sup>(4, 35, 37)</sup>

PERFORMANCE	GOAL
ANALYTICAL	<ul style="list-style-type: none"> <li>• <b>Accurate test results</b> around the cut-off</li> <li>- Qualitative assays: low inter-observer variability</li> <li>- Quantitative assays: <b>low CV (&lt;7.5%)</b></li> </ul>
OPERATIONAL	<ul style="list-style-type: none"> <li>• <b>Easy to use:</b> availability 24 hours, 7 days per week</li> <li>• <b>Rapid turnaround time (TAT):</b> &lt;1 hour</li> </ul>
CLINICAL	<ul style="list-style-type: none"> <li>• <b>High sensitivity (≥97%):</b> safe exclusion in patients with low and intermediate PTP (NPV ≥98%)</li> <li>• <b>Reasonable specificity (&gt;40%):</b> minimize the number of positives that require imaging to confirm the diagnosis</li> <li>• <b>Validated in prospective outcome study:</b> 3-month thromboembolic failure rate in excluded patients should not exceed 3% (upper limit 95% confidence interval)</li> </ul>

Figure 6: NPV vs. VTE prevalence: impact of assay sensitivity



Simulation of the impact of assay sensitivity on the NPV in patients with low, intermediate or high PTP. Safe exclusion requires NPV of 98% or more. Examples include typical D-dimer tests such as a quantitative automated ELFA (Assay A; sensitivity 99%, specificity 40%), a quantitative automated latex-based assay (Assay B; sensitivity 95%, specificity 50%) and a whole-blood agglutination test (Assay C; sensitivity 88%, specificity 70%)<sup>(36)</sup>. No D-dimer assay can be used to safely exclude VTE in patients with high PTP. Highest confidence for safe exclusion in both low and intermediate PTP is offered by the D-dimer assay with the highest sensitivity (Assay A).

## FREQUENTLY ASKED QUESTIONS

### Is 500 µg/L a uniform cut-off for VTE exclusion ?

There is no standardization of D-dimer assays and D-dimer results are either reported as D-dimer units or fibrinogen equivalent units (FEU; 1 µg D-dimer equals 2 µg FEU). Consequently, each method has its own cut-off value for VTE exclusion which needs to be clinically validated in outcome studies<sup>(4)</sup>.

A cut-off value of 500 µg FEU/L has been used in one of the most extensively validated D-dimer assays<sup>(39)</sup>. A combined analysis of 7 prospective outcome studies conducted with this D-dimer method showed that **40% of patients with low/intermediate or unlikely PTP** were below this particular threshold with a 3-month thromboembolic failure rate of only 0.14% (NPV 99.86%) when left untreated.

### Is it safe to exclude VTE based on a negative D-dimer result?

D-dimer should **never be used as a stand-alone test for VTE exclusion** and any negative result should be interpreted **within the clinical context of the patient, including pretest probability**.

Outcome studies combining clinical probability and D-dimer have clearly confirmed the **safety of not treating** suspected VTE patients with a non-high clinical probability and **normal D-dimer**<sup>(5,39)</sup>.

Under certain conditions lower than expected D-dimer results may occur giving rise to false negatives. This may include patients with a small thrombus burden such as distal DVT or subsegmental PE<sup>(4)</sup>. However, the clinical relevance of small clots in these locations is debated<sup>(27)</sup>. Moreover, despite the limited sensitivity for distal DVT or subsegmental PE, the safety of not treating suspected VTE patients with normal D-dimer and non-high clinical probability has been widely demonstrated<sup>(5,39)</sup>. **The crucial point for clinicians is that patients with normal D-dimer levels have an uneventful 3-months follow-up.**

**Clinically relevant false negatives** may occur in suspected VTE patients with **high PTP, long duration of symptoms** (more than one week) or receiving **anticoagulants**<sup>(4, 6, 29)</sup>. Therefore, under these conditions it is not recommended to use D-dimer for VTE exclusion.

**Does a positive D-dimer result indicate the patient has VTE?**

D-dimer is known to have **moderate specificity** for VTE and elevated D-dimer levels (i.e. above VTE rule-out cut-off) are observed in many clinical conditions (see **Table 8**). The likelihood for VTE rises with increasing D-dimer levels, which suggests the potential value of a separate rule-in cut-off<sup>(4)</sup>. However, **a reliable rule-in cut-off level has not been established**.

Even if there is a cut-off above which D-dimer is specific enough to rule in the diagnosis, only very few patients will have a D-dimer above this level, limiting the usefulness of the test. Furthermore, clinicians would be reluctant to accept the diagnosis of DVT or PE based on a D-dimer test alone and would still request additional imaging<sup>(4)</sup>.

Therefore, **D-dimer should only be used as an exclusion test**.

**Can D-dimer be used for VTE exclusion in special populations?**

D-dimer is elevated in the **elderly**, **patients with cancer**, the majority of hospitalized patients, patients with **renal impairment** and a large proportion of **patients with previous VTE**<sup>(4, 40)</sup>. In combination with a clinical prediction rule, it is **still safe to use D-dimer for exclusion in these patient populations**<sup>(4, 6, 40)</sup>. On the other hand, the **clinical usefulness is lower** due to the fact that a lower proportion of suspected VTE can be excluded. The number needed to test (NNT) to exclude one VTE event is about 3 in unselected outpatients (i.e. the exclusion rate is 33%), but this figure is 2 to 10-fold higher in patients with previous VTE (NNT=6), cancer (NNT=9), elderly outpatients (NNT=20), renal impairment (NNT=9) and non-surgical inpatients (NNT=30)<sup>(4, 40)</sup>.

Since D-dimer levels increase with age, their clinical utility for VTE exclusion is reduced in the elderly<sup>(28)</sup>. To **improve the efficiency of PE exclusion in older patients**, while maintaining safety, a simple algorithm for an **age-adjusted D-dimer cut-off** has been derived<sup>(41)</sup>. In patients **above 50 years** of age the optimal cut-off is defined as **patient's age x 10**.

50 years

500 µg/L (conventional cut-off) | age x 10 µg/L

The utility of the age-adjusted cut-off for PE was validated in a large prospective outcome study (**ADJUST-PE**)<sup>(42)</sup>. Compared with the conventional single cut-off, 12% more exclusions were obtained with the age-adjusted cut-off, with the most pronounced effect in elderly patients (**5-fold higher exclusion rate in patients 75 years or older**). Importantly, this increased diagnostic yield did not affect safety because the 3-month thromboembolic failure rate in patients with D-dimer  $\geq 500 \mu\text{g/L}$  but below the age-adjusted cut-off was only 0.3% (95% CI 0.1-1.7%) with the upper limit of the 95% confidence interval well below the acceptable safety margin of 3%.

Validation of the age-adjusted D-dimer cut-off in suspected DVT patients is in progress (**ADJUST-DVT**; ClinicalTrials.gov Identifier: NCT02384135).


**D-dimer is not recommended for VTE exclusion in pregnant women**<sup>(27)</sup>. The main reason is its progressive increase with gestational age. Adapted D-dimer cut-offs have been proposed, but lack validation in prospective outcome studies<sup>(43)</sup>. Furthermore, there are no CPR's that have been properly validated for use in pregnant women with suspected VTE<sup>(27)</sup>.

**What is the difference between two- and three-level CPR's?**

Since the NPV is influenced by disease prevalence, the purpose of a CPR is to assess whether a patient has a **sufficiently low pretest probability to allow safe exclusion by D-dimer testing**. To this end, validated CPR's allow stratification in **three categories (low, intermediate, high) or two categories (unlikely, likely)**; see **Table 6**. Both approaches have a similar accuracy, with a DVT/PE prevalence below 10% in low or unlikely categories. For clinical decision-making, it is also relevant to consider the proportion of patients classified in a given category, because this determines the proportion in which D-dimer can be applied. An example is shown in **Figure 7** for the Wells PE score.

With a **highly sensitive D-dimer assay**, the **three-level rule will be more efficient**. Such an assay can be used in **both low and intermediate PTP categories** which account for 90% of all suspected patients as opposed to 70% for the unlikely category with the Wells PE score (**Figure 7**). Conversely, for a **moderately sensitive D-dimer assay**, the diagnostic yield can be improved by selecting the **two-level score**. In this case, the proportion of patients in which D-dimer can be safely applied for exclusion will be increased from 60% to 70% (**Figure 7**).

**Figure 7: Distribution of pretest probability categories in the Wells PE score**



**Can D-dimer be used to guide the duration of anticoagulation therapy?**

Following diagnosis of VTE, oral anticoagulant therapy (OAT) is necessary to prevent recurrence<sup>(18)</sup>. Decisions on duration of OAT are guided by the risk of recurrent VTE after OAT discontinuation, the risk of major bleeding (1-3% per year when on OAT) as well as the case-fatality rates of both events which is 2-3-fold higher for major bleeding than for recurrent VTE<sup>(44)</sup>.

In provoked VTE patients with a transient and reversible risk factor (e.g. surgery, trauma, prolonged immobilization), who have a low risk of recurrence, a short OAT duration (<3 months) is adequate because the risk of dying from major bleeding outweighs the risk of dying from recurrent VTE<sup>(18)</sup>. In patients with a high risk of VTE recurrence (e.g. cancer), extended OAT duration is recommended because the risk of dying from recurrent VTE outweighs the risk of dying from bleeding<sup>(18)</sup>.

Up to 50% of patients with a first VTE event are characterized as unprovoked VTE (i.e. without a known provoking cause). **The optimal duration of OAT for unprovoked VTE is an important unanswered question in VTE management**<sup>(45)</sup>.

Compared to provoked VTE, these patients have about a 2-fold higher recurrence risk following OAT discontinuation<sup>(9)</sup>. Consequently, extended or indefinite anticoagulation may be required<sup>(18)</sup>. To justify this decision, the risk of fatal VTE should outweigh the risk of fatal bleeding in the long run. However, given the balanced risks of fatal VTE or fatal bleeding in unselected unprovoked VTE, clinicians do not have clear guidance on whether to continue or discontinue OAT after the standard period of 5-7 months.

The solution will be to focus on an **individualized approach** based on **risk predictors** that would identify unprovoked VTE patients with sufficiently low or high risk for recurrence to better justify the decision to discontinue or continue OAT. **Single predictors such as D-dimer are not useful in isolation** because they do not predict a low enough annual recurrence rate (<3%) to justify OAT discontinuation<sup>(45)</sup>.

The **REVERSE study** derived a **clinical decision rule, HERDOO2**, which is simple to use and integrates **D-dimer** measurement with **clinical and demographic predictors (Table 10)**<sup>(46)</sup>. **The rule identifies about 1 in 4 unprovoked VTE patients at low risk of VTE recurrence who may be able to safely discontinue anticoagulation.**

The REVERSE study confirmed previously documented high annual recurrence risk in males (13.7%), but could not find any predictors to identify low risk men. In females, the rule identified high- and low-risk subgroups of about equal size with annual recurrence risk of 14.1% and 1.6%, respectively. The annual VTE risk in women with 0 or 1 risk factor appears sufficiently low (<3%) to justify safe discontinuation of OAT after 5-7 months. The safety and efficacy of this approach has been validated in the REVERSE II study, a large prospective outcome study involving over 3,000 patients<sup>(49)</sup>.

**Table 10: HERDOO2 clinical decision rule**<sup>(49)</sup>

**Women with unprovoked VTE and 0 or 1 of the following features may be able to safely discontinue OAT after 5-7 months:**

- Post-thrombotic signs:  
**H**yperpigmentation, **E**dema or **R**edness in either leg
- **D**-dimer  $\geq 250$   $\mu\text{g/L}$
- **O**besity: BMI  $\geq 30$   $\text{kg/m}^2$
- **O**lder age: age  $\geq 65$  years

**NOTES:**

- All predictors are assessed while the patient is still on OAT after 5-7 months.

**Is there a place for D-dimer in other clinical scenarios?**

In conjunction with other routinely available laboratory parameters, D-dimer is part of a scoring system to diagnose the presence of **disseminated intravascular coagulation (DIC)**<sup>(47)</sup>. DIC is a serious complication of sepsis, cancer, and a variety of other disorders with systemic activation of blood coagulation.

The combined use of a clinical risk stratification score and D-dimer is a promising tool for the safe exclusion of **acute aortic dissection**<sup>(48)</sup>.

## REFERENCES

- Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. *J Thromb Haemost* 2013;11:412-22.
- Le Gal G, Bounameaux H. Diagnosing pulmonary embolism: running after the decreasing prevalence of cases among suspected patients. *J Thromb Haemost*. 2004; 2: 1244-6.
- Newman DH, Schriger DL. Rethinking testing for pulmonary embolism: less is more. *Ann Emerg Med*. 2011;57:622-627.e3.
- Righini M, Perrier A, De Moerloose P, Bounameaux H. D-dimer for venous thromboembolism diagnosis: 20 years later. *J Thromb Haemost*. 2008; 6: 1059-71.
- Ten Cate-Hoek AJ, Prins MH. Management studies using a combination of D-dimer test result and clinical probability to rule out venous thromboembolism: a systematic review. *J Thromb Haemost*. 2005; 3: 2465-70.
- Bruinstroop E, van de Ree MA, Huisman MV. The use of D-dimer in specific clinical conditions: a narrative review. *Eur J Intern Med*. 2009;20:441-6.
- ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. *J Thromb Haemost*. 2014;12:1580-90.
- Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost*. 2007; 98: 756-64.
- Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica*. 2007; 92: 199-205.
- Mahan CE, Borrego ME, Woerschling AL, Federici R, Downey R, Tiongson J, Bieniarz MC, Cavanaugh BJ, Spyropoulos AC. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. *Thromb Haemost*. 2012;108:291-302.
- Schellong SM, Bounameaux H, Büller HR. Venous thromboembolism. In: *The ESC Textbook of Cardiovascular Medicine*, 2nd edition. Camm AJ, Lüscher TF, Serruys PW (eds), Oxford University Press, Oxford, UK, 2009.
- Kearon C. Natural history of venous thromboembolism. *Circulation*. 2003; 107(Suppl. 1): 122-30.
- Flinterman LE, Van Der Meer FJ, Rosendaal FR, Doggen CJ. Current perspective of venous thrombosis in the upper extremity. *J Thromb Haemost*. 2008; 6: 1262-6.
- Anderson FA, Spencer FA. Risk factors for venous thromboembolism. *Circulation*. 2003; 107 (Suppl.1): I9-16.
- Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svtil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J*. 2014;35:3033-69, 3069a-3069k.
- White RH. The epidemiology of venous thromboembolism. *Circulation*. 2003;107(Suppl1):14-8.
- Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(Suppl):e195S-226S.
- Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(Suppl):e419S-94S.
- Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, Perrier A. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. *Ann Intern Med*. 2006;144:165-71.
- Anderson DR, Kovacs MJ, Kovacs G, Stiell I, Mitchell M, Khoury V, Dryer J, Ward J, Wells PS. Combined use of clinical assessment and D-dimer to improve the management of patients presenting to the emergency department with suspected deep vein thrombosis (the EDITED Study). *J Thromb Haemost*. 2003;1:645-51.
- Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med*. 2003;349:1227-35.
- Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. *Thromb Haemost*. 2000;83:416-20.
- Gibson NS, Sohne M, Kruij M, Tick LW, Gerdes VE, Bossuyt PM, Wells PS, Buller HR; Christopher study investigators. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. *Thromb Haemost*. 2008;99:229-34.
- Klok FA, Mos IC, Nijkeuter M, Righini M, Perrier A, Le Gal G, Huisman MV. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. *Arch Intern Med*. 2008;168:2131-6.
- Wells PS, Owen C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis? *JAMA*. 2006;295:199-207.
- Ceriani E, Combescurc C, Le Gal G, Nendaz M, Perneger T, Bounameaux H, Perrier A, Righini M. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. *J Thromb Haemost*. 2010;8:957-70.
- Le Gal G, Righini M. Controversies in the diagnosis of venous thromboembolism. *J Thromb Haemost*. 2015;13 (Suppl.1):S259-65.
- Righini M, Nendaz M, Le Gal G, Bounameaux H, Perrier A. Influence of age on the cost-effectiveness of diagnostic strategies for suspected pulmonary embolism. *J Thromb Haemost*. 2007;5:1869-77.
- Gibson NS, Sohne M, Gerdes VE, Nijkeuter M, Buller HR. The importance of clinical probability assessment in interpreting a normal D-dimer in patients with suspected pulmonary embolism. *Chest*. 2008;134:789-93.
- Roy PM, Meyer G, Vielle B, Le Gall C, Verschuren F, Carpentier F, Leveau P, Furber A; EMDEPU Study Group. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. *Ann Intern Med*. 2006;144:157-64.

31. Venkatesh AK, Kline JA, Courtney DM, Camargo CA, Plewa MC, Nordenholz KE, Moore CL, Richman PB, Smithline HA, Beam DM, Kabrhel C. Evaluation of pulmonary embolism in the emergency department and consistency with a national quality measure: quantifying the opportunity for improvement. *Arch Intern Med.* 2012;172:1028-32.
32. Konstantinides S, Goldhaber SZ. Pulmonary embolism: risk assessment and management. *Eur Heart J.* 2012;33:3014-22.
33. Piran S, Le Gal G, Wells PS, Gandara E, Righini M, Rodger MA, Carrier M. Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. *Thromb Res.* 2013;132:515-9.
34. Bockenstedt P. D-dimer in venous thromboembolism. *N Engl J Med.* 2003;349:1203-4.
35. Tripodi A. D-dimer testing in laboratory practice. *Clin Chem.* 2011;57:1256-62.
36. Di Nisio M, Squizzato A, Rutjes AW, Büller HR, Zwiderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. *J Thromb Haemost.* 2007;5:296-304.
37. CLSI. Quantitative D-dimer for the exclusion of thromboembolic disease; Approved Guideline. CLSI document H59-A. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2011.
38. Kruij MJ, Leclercq MG, van der Heul C, Prins MH, Büller HR. Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. *Ann Intern Med.* 2003;138:941-51.
39. Carrier M, Righini M, Djurabi RK, Huisman MV, Perrier A, Wells PS, Rodger M, Willemin WA, Le Gal G. VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies. *Thromb Haemost.* 2009;101:886-92.
40. Robert-Ebadi H, Bertoletti L, Combescurc C, Le Gal G, Bounameaux H, Righini M. Effects of impaired renal function on levels and performance of D-dimer in patients with suspected pulmonary embolism. *Thromb Haemost.* 2014;112:614-20.
41. Douma RA, le Gal G, Söhne M, Righini M, Kamphuisen PW, Perrier A, Kruij MJ, Bounameaux H, Büller HR, Roy PM. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. *BMJ.* 2010;340:c1475.
42. Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le Gal G. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. *JAMA.* 2014;311:1117-24.
43. Chan WS, Lee A, Spencer FA, Chumilal S, Crowther M, Wu W, Johnston M, Rodger M, Ginsberg JS. D-dimer testing in pregnant patients: towards determining the next "level" in the diagnosis of DVT. *J Thromb Haemost.* 2010;8:1004-11.
44. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. *Ann Intern Med.* 2010;152:578-89.
45. Rodger M, Carrier M, Gandara E, Le Gal G. Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit. *Blood Rev.* 2010;24:171-8.
46. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, Solymoss S, Crowther M, Perrier A, White R, Vickers L, Ramsay T, Betancourt MT, Kovacs MJ. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. *CMAJ.* 2008;179:417-26.
47. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. *Crit Care Med.* 2004;32:2416-21.
48. Nazerian P, Morello F, Vanni S, Bono A, Castelli M, Forno D, Gigli C, Soardo F, Carbone F, Lupia E, Grifoni S. Combined use of aortic dissection detection risk score and D-dimer in the diagnostic workup of suspected acute aortic dissection. *Int J Cardiol.* 2014;175:78-82.
49. Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, Righini M, Mismetti P, Kearon C, Meyer G, Elias A, Ramsay T, Ortel TL, Huisman MV, Kovacs MJ; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. *BMJ.* 2017;356:j1065

## LIST OF ABBREVIATIONS

<b>BNP</b>	Brain (or B-type) natriuretic peptide
<b>CI</b>	Confidence interval
<b>CPR</b>	Clinical prediction rule
<b>CTEPH</b>	Chronic thromboembolic pulmonary hypertension
<b>CTPA</b>	Computerized tomographic pulmonary angiography
<b>CUS</b>	Compression ultrasound
<b>CV</b>	Coefficient of variation
<b>DIC</b>	Disseminated intravascular coagulation
<b>DVT</b>	Deep vein thrombosis
<b>ED</b>	Emergency department
<b>ELISA</b>	Enzyme-linked immunosorbent assay
<b>ELFA</b>	Enzyme-linked immunosorbent assay
<b>ESC</b>	European Society of Cardiology
<b>FEU</b>	Fibrinogen equivalent unit (500 µg FEU/L = 250 µg D-dimer/L)
<b>HERDOO2</b>	Acronym for a clinical decision rule in women with unprovoked VTE based on post-thrombotic signs ( <b>H</b> yperpigmentation, <b>E</b> dema, <b>R</b> edness), <b>D</b> -dimer, <b>O</b> besity and <b>O</b> lder age. Women with a total score of two or more points are at high risk of VTE recurrence
<b>NNT</b>	Number needed to test to exclude one VTE event (e.g. NNT=3 if 33% of D-dimer test results are below the cut-off)
<b>NPV</b>	Negative predictive value
<b>NT-proBNP</b>	N-terminal pro B-type natriuretic peptide
<b>OAT</b>	Oral anticoagulant therapy
<b>PE</b>	Pulmonary embolism
<b>PESI</b>	Pulmonary Embolism Severity Index
<b>PPV</b>	Positive predictive value
<b>PTP</b>	Pre-test probability
<b>PTS</b>	Post-thrombotic syndrome
<b>REVERSE</b>	Acronym for study on recurrent VTE: <b>R</b> ecurrent <b>V</b> enous thromboembolism <b>R</b> isk Stratification <b>E</b> valuation
<b>RVD</b>	Right ventricular dysfunction
<b>sPESI</b>	Simplified Pulmonary Embolism Severity Index
<b>VTE</b>	Venous thromboembolism
<b>V/Q scan</b>	Ventilation (V) and perfusion (Q) lung scintigraphy